12,372 trials
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Endurance Time (Seconds) — 68.3; 9.8 Seconds
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 — 8.4; 11.2; 11.0; 16.5 percent
Symptomatic Refractory Resistant Carcinoid Disease
Primary: Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment. — 13.5; 28.2; 100; 20.0 Percentage of Participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84 — 0.094; 0.174 Liters — p=<0.001
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 26 — -0.17; -0.79; -0.94; -0.82 Percent — p=<0.001
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84 — 0.108; 0.130 Liters — p=0.282
Carcinoma · Non-Small-Cell Lung
Primary: Overall Survival — 248; 253 Days — p=0.4687
Parkinson's Disease
Primary: The Difference of Time Spent in the 'on' State Without Troublesome Dyskinesia Based on Patient Motor Diaries as Compared to the Baseline. — 4.6; 0 Hours per day
Caries
Primary: Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF) — 38.05; 41.06 Percentage SMHR…
Asthma
Primary: Number of Participants With At Least One Adverse Event (AE) — 5; 8 participants
Opiate Dependence
Primary: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study. — 37 participants
Chronic Motor or Vocal Tic Disorder · Tourette's Disorder
Primary: Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7) — -9.62; -14.97 units on a scale
Type 2 Diabetes
Primary: Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1 — -0.36; -0.34; -0.49; -0.01 % (units of HbA1c) — p=<0.05
Mycoses · Candidiasis · Aspergillosis
Primary: Maximum Plasma Itraconazole Concentration (Cmax) — 2.90; 2.30; 1.79; 9.20 mcg/ml
Osteoarthritis · Rheumatoid Arthritis · Chronic Low Back Pain
Primary: Number of Participants With Treatment Emergent Adverse Events — 76 participants